12. Other Expense

Other income (expense), net for the three and nine months ended September 30, 2015 and 2014 included the following:


	Three months ended September 30,				Nine months ended September 30,
	2015		2014		2015		2014
Restructuring, asset impairment and related charges	$	(35)	$	(71)	$	(57)	$	(71)
Strategic transaction costs		(13)				(19)
Foreign currency exchange gain (loss)		2		1		10		(1)
Other income (expense), net		2		(3)		7		2
	$	(44)	$	(73)	$	(59)	$	(70)

For the three and nine months ended September 30, 2015, the restructuring, asset impairment and related charges primarily related to the Latin America, Asia Pacific and North America regions (see Note 5 for additional information).

During the three and nine months ended September 30, 2014, the Company recorded charges of $79 million for restructuring, asset impairment and related charges of which $71 million was recorded to other expense. These charges were primarily related to the Company’s Asia Pacific restructuring (see Note 5 for additional information).

On September 1, 2015, the Company completed the Vitro Acquisition. For the three and nine months ended September 30, 2015, the strategic transaction costs primarily related to this acquisition.